Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
NSCLC: early-phase trial registry
48 of 72 indexed NSCLC trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #191 of 28,707 conditions by registered trial count.
72 US clinical trials · 48 currently recruiting · #191 of 28,707 conditions by registered trial count
NSCLC: 72 US clinical trials tracked, 48 recruiting.
NSCLC is the subject of 72 registered US clinical trials on ClinicalTrials.gov, 48 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 55 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 6 of these trials.
Enrollment posture brief
Registry condition nsclc
OPEN 48 | RECR 67% | LATE 8 | EARLY 55 | RANK #191 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
NSCLC lists 48 open slots (67% of 72 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for NSCLC on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
NSCLC is recruiting above its size-band peers.
48 of 72 indexed trials (66.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of NSCLC trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 6 of 72 trials (8.3%). 58 distinct sponsors appear on at least one study for this condition label.
-
Typical NSCLC enrolment sits around 160 participants.
Median target enrolment is 160 among the 72 trials that report a genuine target (sentinel values excluded). 32 of those (44.4%) plan for fewer than 100 participants.
-
NSCLC research is mostly interventional.
67 interventional and 5 observational studies make up this index (93.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
72 total, page 2 of 2
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
Cullinan Therapeutics
NCT05117476
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
BioAtla
NCT05180799
Epidemiology of Young Lung Cancer - Survey
Addario Lung Cancer Medical Institute
NCT04640259
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
Black Diamond Therapeutics
NCT05256290
Study to Evaluate D-1553 in Subjects With Solid Tumors
InventisBio Co.
NCT04585035
Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
Alliance Foundation Trials
NCT05798663
Study of Oral MRT-2359 in Selected Cancer Patients
Monte Rosa Therapeutics
NCT05546268
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
A2 Biotherapeutics
NCT05736731
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
Memorial Sloan Kettering Cancer Center
NCT03808662
Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
Nasser Hanna
NCT04367311
Lorlatinib Continuation Study
Pfizer
NCT05144997
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Pfizer
NCT05059522
Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
NCT03999710
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
Joseph J. Cullen, MD, FACS
NCT02905591
Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
Memorial Sloan Kettering Cancer Center
NCT04716946
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Dan Zandberg
NCT04157985
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Pfizer
NCT04672460
A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors
Halozyme Therapeutics
NCT02563548
Study of the CD40 Agonistic Monoclonal Antibody APX005M
Apexigen America
NCT02482168
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
Jacobio Pharmaceuticals Co.
NCT05002270
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
NCT03758781
Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC
Case Comprehensive Cancer Center
NCT03535363
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 41 |
| Phase 2 | 14 |
| Phase 3 | 7 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on NSCLC records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on NSCLC trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this NSCLC page
72 registered trials, 48 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 48 NSCLC trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most NSCLC trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This NSCLC condition card totals 72 registered trials; most-linked intervention Pembrolizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.